当前位置: 首页 >> 检索结果
241. Heart Rate Mystery Unveiled: Sex Differences in Human Sinoatrial Node Genes and Female Tachycardia.
作者: Ning Li.;Amy Webb.;James Kennelly.;Roshan Sharma.;Bryan A Whitson.;Peter J Mohler.;John D Hummel.;Jichao Zhao.;Vadim V Fedorov.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013534页
Despite over a century of clinical electrocardiographic studies showing that women exhibit a faster resting heart rate (HR), the mechanisms underlying sex differences in HR remain unresolved. Moreover, inappropriate sinus tachycardia primarily affects women, whereas men are at a higher risk for conduction block and atrial fibrillation. We hypothesized that the sexual dimorphism of genes responsible for sinoatrial node (SAN) pacemaking and signaling pathways may contribute to the sex differences in HR and susceptibility to arrhythmias.
242. Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.
作者: Phyllis M Thangaraj.;Evangelos K Oikonomou.;Lovedeep S Dhingra.;Arya Aminorroaya.;Rahul H Jayaram.;Marc A Suchard.;Rohan Khera.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011306页
Assessing the generalizability of randomized clinical trials (RCTs) to real-world patients remains challenging. We propose a multidimensional metric to quantify the representativeness of an RCT cohort in an electronic health record (EHR) population and estimate real-world effects based on individualized treatment effects observed in the RCT.
243. Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications.
作者: Pavan Reddy.;Fernando J Rodriguez-Weisson.;Giorgio A Medranda.;Ilan Merdler.;Matteo Cellamare.;Paul Gordon.;Afshin Ehsan.;Puja Parikh.;Thomas Bilfinger.;Maurice Buchbinder.;David Roberts.;Nicholas Hanna.;Itsik Ben-Dor.;Lowell F Satler.;Hector M Garcia-Garcia.;Federico M Asch.;Gaby Weissman.;Anita Sadeghpour.;Christian C Schults.;Ron Waksman.;Toby Rogers.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014802页
Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm.
247. Correction to: Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke.
作者: Jingu Lee.;Brett Balzraine.;Alexis Schweizer.;Vasilisa Kuzmanova.;Yousang Gwack.;Babak Razani.;Jin-Moo Lee.;Deane F Mosher.;Jaehyung Cho.
来源: Circulation. 2025年151卷16期e961页 248. Response by Jia et al to Letter Regarding Article, "Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial".249. Cell Painting and Machine Learning Distinguish Fibroblasts From Nonfailing and Failing Human Hearts.
作者: Joshua G Travers.;Jenna Tomkinson.;Marcello Rubino.;Marion Delaunay.;Michael R Bristow.;Gregory P Way.;Timothy A McKinsey.
来源: Circulation. 2025年151卷16期1207-1210页 250. Letter by Xu et al Regarding Article, "Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial".253. Left Ventricular Unloading With Assist Device Implantation Increases GJA1-20k Expression in Patients With Arrhythmogenic Cardiomyopathy.
作者: Steven E Valdez.;Lindsey A Taylor.;Craig H Selzman.;Stavros G Drakos.;Robin M Shaw.;Joseph A Palatinus.
来源: Circ Heart Fail. 2025年18卷5期e012174页 254. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
255. Dissecting the Genetic Architecture of Intracranial Aneurysms.
作者: Shaunak S Adkar.;Julie Lynch.;Ryan B Choi.;Tanmoy Roychowdhury.;Renae L Judy.;Kaavya Paruchuri.;Dong-Chuan Go.;Sharika Bamezai.;John Cabot.;Sabina Sorondo.;Michael G Levin.;Dianna M Milewicz.;Cristen J Willer.;Pradeep Natarajan.;Saiju Pyarajan.;Kyong-Mi Chang.;Scott Damrauer.;Phil Tsao.;Stephen Skirboll.;Nicholas J Leeper.;Derek Klarin.
来源: Circ Genom Precis Med. 2025年18卷3期e004626页
The genetic risk of intracranial aneurysm (IA) development has been ascribed to the genetic risk of smoking exposure and hypertension. The relationship of IA to other cardiovascular traits and the contribution of IA risk loci to aberrant gene programs within cerebrovascular cell types remains unclear.
256. Clinical Validity of Autosomal Dominant ALPK3 Loss-of-Function Variants as a Cause of Hypertrophic Cardiomyopathy.
作者: Sophie Hespe.;Emma S Singer.;Chloe Reuter.;Brittney Murray.;Elizabeth Jordan.;Jessica Chowns.;Stacey Peters.;Megan Mayers.;Belinda Gray.;Ray E Hershberger.;Anjali T Owens.;Christopher Semsarian.;Amber Waddell.;Babken Asatryan.;Emma Owens.;Courtney Thaxton.;Mhy-Lanie Adduru.;Kailyn Anderson.;Emily E Brown.;Lily Hoffman-Andrews.;Fergus Stafford.;Richard D Bagnall.;Lucas Bronicki.;Bert Callewaert.;C Anwar A Chahal.;Cynthia A James.;Olga Jarinova.;Andrew P Landstrom.;Elizabeth M McNally.;Laura Muiño-Mosquera.;Victoria Parikh.;Roddy Walsh.;Bess Wayburn.;James S Ware.;Benjamin L Parker.;Enzo R Porrello.;David A Elliott.;James W McNamara.;Jodie Ingles.
来源: Circ Genom Precis Med. 2025年18卷3期e004976页 257. High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study.
作者: Jarett D Berry.;Noor Zabad.;Douglas Kyrouac.;David Leonard.;Carolyn E Barlow.;Andjelka Pavlovic.;Kerem Shuval.;Benjamin D Levine.;Laura F DeFina.
来源: Circulation. 2025年151卷18期1299-1308页
High-volume physical activity (PA) is associated with a higher prevalence of subclinical coronary artery disease (CAD). However, the clinical significance of subclinical CAD among high-volume exercisers remains incompletely understood, and the dose-response relationship between high-volume PA and clinical CAD events remains uncertain.
258. Ca2+ Cycling Alteration in a Porcine Model of Right Ventricular Dysfunction.
作者: Fabrice Antigny.;Rui Luo.;Romain Perrier.;Bastien Masson.;Guillaume Fadel.;Grégoire Ruffenach.;Anaïs Saint-Martin Willer.;Ali Akamkam.;Julien Grynblat.;Xavier Jaïs.;Jerôme Le Pavec.;Simon Dang Van.;Dorothée Brunet.;Florence Lefebvre.;Garance Gérard.;Séverine Domenichini.;Angèle Boët.;Julien Guihaire.;Ana-Maria Gomez.;David Montani.;Jean-Pierre Benitah.;Marc Humbert.;Olaf Mercier.;Jessica Sabourin.
来源: Circ Heart Fail. 2025年18卷5期e012293页
Pulmonary hypertension is a severe disease with high mortality rates due to right ventricular (RV) failure. The molecular and cellular processes involved in RV remodeling, including Ca2+ handling, remain elusive due to the lack of relevant animal models. In this study, we aim to understand better the pathophysiological mechanisms involved in RV failure.
259. Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension.
作者: Niamh Errington.;Li Zhou.;Christopher J Rhodes.;Yiu-Lian Fong.;Lihan Zhou.;Sokratis Kariotis.;Eileen Harder.;Aaron Waxman.;Timothy Jatkoe.;John Wharton.;A A Roger Thompson.;Robin A Condliffe.;David G Kiely.;Luke S Howard.;Mark Toshner.;Cheng He.;Dennis Wang.;Martin R Wilkins.;Allan Lawrie.
来源: Circ Genom Precis Med. 2025年18卷3期e004862页
Patients with pulmonary hypertension (PH) are classified based on disease pathogenesis and hemodynamic drivers. Classification informs treatment. The heart failure biomarker NT-proBNP (N-terminal pro-B-type natriuretic peptide) is used to help inform risk but is not specific to PH or sub-classification groups. There are currently no other biomarkers in clinical use to help guide diagnosis or risk.
260. Intermediate Monocytes and High Levels of Chemokine CCL3 Are Associated With Increased Risk of Atrial Fibrillation in the General Population.
作者: Kari Anne Sveen.;J Gustav Smith.;Isabel Goncalves.;Andreas Edsfeldt.;Daniel Engelbertsen.;Linda S Johnson.;Olle Melander.;Gunnar Engström.;Jan Nilsson.;Harry Björkbacka.;Eva Bengtsson.
来源: Circ Arrhythm Electrophysiol. 2025年18卷5期e013621页 |